Pinorubin (pirarubicin)

P3, N=236, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Initiation date: Mar 2026 --> Jun 2026

P3, N=236, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Diffuse large B-cell lymphoma (DLBCL) can undergo stepwise immunophenotypic and molecular evolution over decades, progressing from a germinal Center B-cell-like (GCB)-like phenotype to an activated B-cell -like/non-GCB pattern (MUM1+, CD30+) and ultimately to an aggressive anaplastic variant.The cell-of-origin profile and its associated molecular features are not necessarily static; thus, therapeutic strategies for relapsed DLBCL should be tailored to the current disease state rather than relying on the signature at initial diagnosis.Longitudinal re-evaluation through repeat biopsies is imperative to capture the evolving landscape of the malignancy, ensuring that treatment selection is guided by the most recent pathological and molecular findings.

Rutin mitigates THP-induced cardiotoxicity and enhances chemotherapeutic efficacy via the novel miR-129-1-3p/GRIN2D pathway. Our data show miR-129-1-3p to be an essential mediator, and suggest that the rutin-miR-129-1-3p-GRIN2D axis is a favorable target for improving the safety and effectiveness of breast cancer chemotherapy.

P1, N=30, Recruiting, Xijing Hospital | Not yet recruiting --> Recruiting

The patient received four cycles of neoadjuvant etoposide plus carboplatin chemotherapy, followed by radical left nephroureterectomy with bladder cuff excision. Adjuvant therapy included intravesical pirarubicin and six cycles of dual PD-1 blockade with toripalimab and vedicitumab...This case demonstrates the potential efficacy of integrating ICIs with standard treatment for advanced ureteral SCNEC. The durable response observed underscores the need for further research into early immunotherapy use and biomarker-guided therapeutic strategies.

The impact of HER2 expression on the recurrence-free survival (RFS) of patients with intravesical anthracycline (epirubicin or pirarubicin) instillation after transurethral resection of bladder tumor (TURBT) was evaluated. In the patients treated with intravesical anthracycline instillation, HER2 high-expression was associated with a shorter RFS (P<0.001). HER2 high-expression seems to be not only associated with worse clinicopathological features of NMIBC but also a poor RFS in NMIBC patients treated with anthracycline instillation after TURBT.

In addition, compared with the control group, the tumor volume in the THP@TEVs group was reduced by approximately 62.1% (p<0.001, n=5) and no histopathological changes were observed in major organs (such as heart, liver, spleen, lungs, and kidneys) upon H&E staining. This study provides a precise, low-toxicity chemotherapy and immune synergistic strategy for TNBC and expands the potential of TEVs in tumor therapy.

P1, N=30, Not yet recruiting, Xijing Hospital

The patient underwent 4 courses of chemotherapy with ifosfamide and pirarubicin. The findings from this case highlight the morphologic and immunohistochemical features that are diagnostic of this rare uterine tumor. Furthermore, this report summarizes the morphologic criteria for malignancy and the key points for its differential diagnosis.

QSHWC alleviates anthracycline-induced cardiotoxicity by targeting cardiac pyroptosis through the PI3K/AKT pathway, while providing a multi-target therapeutic strategy.

This case underscores the imperative for multimodal integration (surgery, chemotherapy, and ICIs) to optimize survival in advanced renal pelvic adenocarcinoma while highlighting the necessity of dynamic therapeutic adaptation-including regimen rechallenge and tyrosine kinase inhibitor combinations-to address recurrence and resistance. Proactive toxicity management (e.g., dose de-escalation for renal injury) and rigorous biomarker-driven surveillance (serial CA19-9 tracking with 3-month imaging) emerge as critical strategies to balance efficacy and safety in this aggressive malignancy.